Go Pro
NASDAQ:SBFM

Sunshine Biopharma 11/5/2024 Earnings Report

Sunshine Biopharma logo
$0.84 -0.03 (-3.63%)
As of 10:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Sunshine Biopharma EPS Results

Actual EPS
-$9.40
Consensus EPS
$90.00
Beat/Miss
Missed by -$99.40
One Year Ago EPS
N/A

Sunshine Biopharma Revenue Results

Actual Revenue
$8.44 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sunshine Biopharma Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sunshine Biopharma's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Sunshine Biopharma Earnings Headlines

NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles.tc pixel
SBFM Share News Today
See More Sunshine Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email.

About Sunshine Biopharma

Sunshine Biopharma (NASDAQ:SBFM) (NASDAQ:SBFM) is a pharmaceutical and biotechnology company focused on the development of therapies for cancer and other serious diseases. Its research and development activities are centered on proprietary drug candidates intended to address unmet medical needs.

The company’s lead oncology candidate is Adva-27a, a small-molecule topoisomerase II inhibitor being investigated for potential use against advanced solid tumors, including certain cancers that may be resistant to existing treatments. Sunshine Biopharma has also described research involving mRNA-based therapeutic approaches and treatments targeting coronaviruses.

In addition to its biotechnology pipeline, Sunshine Biopharma has pursued pharmaceutical commercialization activities in Canada through its Canadian operations, which are associated with the distribution and sale of prescription and over-the-counter products. The company is headquartered in Montreal, Quebec, and has been led by founder and Chief Executive Officer Dr. Steve N. Slilaty.

View Sunshine Biopharma Profile